Page last updated: 2024-08-24

irinotecan and Intestinal Diseases

irinotecan has been researched along with Intestinal Diseases in 14 studies

Research

Studies (14)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's2 (14.29)18.2507
2000's2 (14.29)29.6817
2010's6 (42.86)24.3611
2020's4 (28.57)2.80

Authors

AuthorsStudies
Dai, QL; Jia, HJ; Rui Bai, S; Wang, XB; Xia, J; Yue He, S; Zhou, M1
Deng, H; Dou, W; Pan, Y; Wang, Y; Xiao, L; Xu, H1
Huang, H; Jiang, W; Jinbo, M; Wang, H; Wang, X; Yu, P; Zhang, G; Zhang, X1
Chang, XY; Dong, L; Jiang, ZP; Jin, WY; Li, ZZ; Shi, JW; Shi, Y; Sun, H; Wu, JS1
Hirao, J; Iguchi, T; Mori, K; Nishiya, T; Saitoh, W; Shirai, M; Takada, S; Tsuji, M1
Chen, S; Feng, M; Guo, S; Hou, Q; Liu, Y; Pan, Y; Sun, L; Wang, P; Wang, Y; Xu, H; Yue, T1
Brunner, T; Grabinger, T; Kostadinova, F; Leist, M; Luks, L; Medema, JP; Zimberlin, C1
Almeida, PR; Batista, GL; Bem, AX; Borges, VF; Brito, GA; Carvalho, CB; Cunha, FQ; Cunha, TM; Leite, CA; Lima-Júnior, RC; Ribeiro, RA; Silva, RL; Teixeira, MA; Wanderley, CW; Wong, DV1
Cunha, FQ; Leite, CA; Lima-Júnior, RC; Mota, JM; Ribeiro, RA; Souza, MH; Wanderley, CW; Wong, DV1
Chang, HJ; Choi, HS; Jeong, SY; Kim, DY; Kim, SY; Oh, JH; Park, JW; Seo, GJ; Shin, A; Yoo, SB1
Chan, E; Chan, SY; Chen, X; Duan, W; Ho, PC; Hu, Z; Huang, M; Li, X; Xu, C; Yang, H; Yang, X; Zhou, S; Zhu, YZ1
Cuzzocrea, S; Dorio, AS; Forini, O; Graziani, G; Lapidus, R; Leonetti, C; Mazzon, E; Muzi, A; Scarsella, M; Tentori, L; Vergati, M; Xu, W; Zhang, J1
Fidler, IJ; Killion, JJ; Kumar, R; Kuniyasu, H; Shinohara, H1
Atsumi, R; Hakusui, H; Suzuki, W1

Reviews

1 review(s) available for irinotecan and Intestinal Diseases

ArticleYear
Irinotecan- and 5-fluorouracil-induced intestinal mucositis: insights into pathogenesis and therapeutic perspectives.
    Cancer chemotherapy and pharmacology, 2016, Volume: 78, Issue:5

    Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothecin; Cytokines; Fluorouracil; Humans; Intestinal Diseases; Irinotecan; Mucositis; Receptors, Cytokine

2016

Other Studies

13 other study(ies) available for irinotecan and Intestinal Diseases

ArticleYear
Artesunate ameliorates irinotecan-induced intestinal injury by suppressing cellular senescence and significantly enhances anti-tumor activity.
    International immunopharmacology, 2023, Volume: 119

    Topics: Animals; Artesunate; Camptothecin; Cellular Senescence; Humans; Intestinal Diseases; Irinotecan; Mice; Neoplasms; TOR Serine-Threonine Kinases

2023
Treatment with S-adenosylmethionine ameliorates irinotecan-induced intestinal barrier dysfunction and intestinal microbial disorder in mice.
    Biochemical pharmacology, 2023, Volume: 216

    Topics: Animals; Caco-2 Cells; Diarrhea; Gastrointestinal Diseases; Humans; Intestinal Diseases; Intestinal Mucosa; Irinotecan; Mice; Occludin; S-Adenosylmethionine; Tight Junctions

2023
Ganciclovir reduces irinotecan-induced intestinal toxicity by inhibiting NLRP3 activation.
    Cancer chemotherapy and pharmacology, 2020, Volume: 85, Issue:1

    Topics: Animals; Antiviral Agents; Apoptosis; Biomarkers; Cell Proliferation; Colonic Neoplasms; Diarrhea; Ganciclovir; Gene Expression Regulation; Humans; Inflammation; Intestinal Diseases; Irinotecan; Male; Mice; Mice, Inbred BALB C; Mice, Nude; NLR Family, Pyrin Domain-Containing 3 Protein; Topoisomerase I Inhibitors; Tumor Cells, Cultured; Xenograft Model Antitumor Assays

2020
Identification of the bioactive components of Banxia Xiexin Decoction that protect against CPT-11-induced intestinal toxicity via UPLC-based spectrum-effect relationship analyses.
    Journal of ethnopharmacology, 2021, Feb-10, Volume: 266

    Topics: Animals; Chromatography, High Pressure Liquid; Diarrhea; Drugs, Chinese Herbal; Female; Intestinal Diseases; Irinotecan; Mice; Mice, Inbred ICR; Tandem Mass Spectrometry; Topoisomerase I Inhibitors

2021
Plasma citrulline is a sensitive safety biomarker for small intestinal injury in rats.
    Toxicology letters, 2018, Oct-01, Volume: 295

    Topics: Animals; Antineoplastic Agents, Phytogenic; Arginine; Biomarkers; Camptothecin; Citrulline; Down-Regulation; Ileum; Intestinal Diseases; Irinotecan; Jejunum; Male; Metabolomics; Rats, Sprague-Dawley; Time Factors

2018
The administration of Escherichia coli Nissle 1917 ameliorates irinotecan-induced intestinal barrier dysfunction and gut microbial dysbiosis in mice.
    Life sciences, 2019, Aug-15, Volume: 231

    Topics: Animals; Caco-2 Cells; Claudin-1; Diarrhea; Dysbiosis; Escherichia coli; Gastrointestinal Diseases; Gastrointestinal Microbiome; Humans; Intestinal Diseases; Intestinal Mucosa; Intestines; Irinotecan; Male; Mice; Mice, Inbred BALB C; Probiotics; Tight Junction Proteins

2019
Ex vivo culture of intestinal crypt organoids as a model system for assessing cell death induction in intestinal epithelial cells and enteropathy.
    Cell death & disease, 2014, May-15, Volume: 5

    Topics: Animals; Apoptosis; Apoptosis Regulatory Proteins; Bcl-2-Like Protein 11; Biological Assay; Caco-2 Cells; Camptothecin; Cisplatin; Dose-Response Relationship, Drug; Epithelial Cells; Humans; Intestinal Diseases; Intestinal Mucosa; Intestine, Small; Irinotecan; Membrane Proteins; Mice; Mice, Inbred C57BL; Mice, Knockout; Organoids; Proto-Oncogene Proteins; Time Factors; Tumor Necrosis Factor-alpha

2014
The Adaptor Protein Myd88 Is a Key Signaling Molecule in the Pathogenesis of Irinotecan-Induced Intestinal Mucositis.
    PloS one, 2015, Volume: 10, Issue:10

    Topics: Animals; Bacteremia; Camptothecin; Diarrhea; Intestinal Diseases; Intestinal Mucosa; Irinotecan; Mice; Mice, Knockout; Mucositis; Myeloid Differentiation Factor 88; Peroxidase; Signal Transduction; Toll-Like Receptor 2; Toll-Like Receptor 9

2015
Intestinal complications after palliative treatment for asymptomatic patients with unresectable stage IV colorectal cancer.
    Journal of surgical oncology, 2010, Jul-01, Volume: 102, Issue:1

    Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cetuximab; Colorectal Neoplasms; Combined Modality Therapy; Female; Follow-Up Studies; Humans; Incidence; Intestinal Diseases; Irinotecan; Male; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Palliative Care; Postoperative Complications; Retrospective Studies; Survival Rate; Treatment Outcome

2010
St. John's Wort modulates the toxicities and pharmacokinetics of CPT-11 (irinotecan) in rats.
    Pharmaceutical research, 2005, Volume: 22, Issue:6

    Topics: Animals; Antineoplastic Agents, Phytogenic; Area Under Curve; Blood Cell Count; Body Weight; Camptothecin; Chromatography, High Pressure Liquid; Diarrhea; Drug Interactions; Half-Life; Hypericum; Intestinal Diseases; Intestinal Mucosa; Irinotecan; Male; Rats; Rats, Sprague-Dawley; Reference Standards; Reproducibility of Results

2005
Inhibition of poly(ADP-ribose) polymerase prevents irinotecan-induced intestinal damage and enhances irinotecan/temozolomide efficacy against colon carcinoma.
    FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 2006, Volume: 20, Issue:10

    Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cell Proliferation; Colonic Neoplasms; Colony-Forming Units Assay; Dacarbazine; Diarrhea; Drug Synergism; Enzyme Inhibitors; Intestinal Diseases; Irinotecan; Organic Chemicals; Poly(ADP-ribose) Polymerase Inhibitors; Temozolomide; Topoisomerase I Inhibitors; Tumor Burden

2006
Prevention of intestinal toxic effects and intensification of irinotecan's therapeutic efficacy against murine colon cancer liver metastases by oral administration of the lipopeptide JBT 3002.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 1998, Volume: 4, Issue:9

    Topics: Adjuvants, Immunologic; Administration, Oral; Animals; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Drug Administration Schedule; Drug Synergism; Intestinal Diseases; Irinotecan; Lipopeptides; Lipoproteins; Liver Neoplasms, Experimental; Macrophage Activation; Macrophages; Mice; Mice, Inbred BALB C

1998
Identification of the metabolites of irinotecan, a new derivative of camptothecin, in rat bile and its biliary excretion.
    Xenobiotica; the fate of foreign compounds in biological systems, 1991, Volume: 21, Issue:9

    Topics: Animals; Bile; Biotransformation; Camptothecin; Chromatography, High Pressure Liquid; Chromatography, Thin Layer; Enterohepatic Circulation; Feces; Glucuronidase; Hydrolysis; Intestinal Diseases; Irinotecan; Lactones; Magnetic Resonance Spectroscopy; Male; Mass Spectrometry; Rats; Rats, Inbred Strains; Spectrometry, Fluorescence

1991